Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TransCon Treprostinil in healthy volunteers
NCT03803163Phase 1Terminated
- Sponsor
- Ascendis Pharma
- Start
- Jan 2015
- Primary completion
- Jun 2015
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of TransCon treprostinil in pulmonary arterial hypertension (PAH), sponsored by Ascendis Pharma. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 42 days. Started Jan 2015; status: terminated.
02
Drugs
TransCon treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT03803163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03803163.